Tempus builds a library of molecular and clinical data as well as a corresponding operating system for data accessibility and use. The company enables physicians to deliver personalized cancer care for patients through its interactive analytical and machine-learning platform. It provides genomic sequencing services and molecular and therapeutic data analysis to empower physicians to make real-time, data-driven decisions. It serves clients in the healthcare sector. The company was founded in 2015 and is based in Chicago, Illinois.
ESPs containing Tempus
The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.
These vendors sell access to their aggregated deidentified datasets, which is used for building, training, and testing AI/ML algorithms, or as the basis for synthetic datasets.
Compete with Tempus?
Ensure that your company and products are accurately represented on our platform.
Tempus's Products & Differentiators
Use our genomic platform to prospectively sequence through clinical trials and retrospectively support research priorities
Research containing Tempus
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Tempus in 27 CB Insights research briefs, most recently on Oct 13, 2022.
Expert Collections containing Tempus
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Tempus is included in 17 Expert Collections, including Digital Health.
Startups recreating how healthcare is delivered
Unicorns- Billion Dollar Startups
Clinical Trials Tech
Companies developing products and services to streamline drug R&D, from drug discovery, pre-clinical testing, and clinical trials.
HLTH is a healthcare event bringing together startups and large companies from pharma, health insurance, business intelligence, and more to discuss the shifting landscape of healthcare
This collection includes startups selling AI SaaS, using AI algorithms to develop their core products, and those developing hardware to support AI workloads.
Latest Tempus News
Nov 23, 2022
Share Arterys , developer of the world’s first internet platform for medical imaging, now part of Tempus, announced its organic growth of products and partnerships to serve radiologists with even faster and more accurate diagnostic tools. “Arterys is at a pivotal point in time in which we are really uniquely positioned to scale our solutions,” said Arterys CEO John Axerio-Cilies . “We’re excited to introduce new partnerships and product updates that will support physicians in delivering personalized, data-driven patient care.” Arterys Breast AI gains traction concluding Breast Cancer Awareness Month Arterys’ Breast AI product has seen rapid expansion, with several new customers recently adopting the cloud-based solution and many more committed to 2023. Three recent technology adopters chose Arterys for different reasons: Related Posts Nov 23, 2022 In Salina, Kansas, Arterys Breast AI’s SaaS model allowed the site to implement advanced technology with an operational budget. In Florida, a national breast company was excited by the breast triage worklist combined with the CAD case score results, helping to direct patients to advanced diagnostic imaging immediately — they will expand the solution over multiple sites nationwide over the next year A third site in Montana found that Arterys was agnostic to multiple gantry vendors and that the cloud solution could be added to the new gantry and deployed to older ones without capital equipment. Arterys enhances ecosystem with new strategic partnerships InferVision — Arterys and InferVision have partnered to offer an optimized AI-driven lung oncology workflow with FDA-cleared detection, segmentation, and follow-up. Using the partnership’s automated selection of nodule types and automated Lung-rads scoring and RECIST increases reporting efficiency. DeepLook Medical — Arterys and DeepLook Medical have joined forces to offer physicians efficiency and remove subjectivity from their oncology workflow. DeepLook’s FDA-cleared DL Precise™ automated segmentation tool has been added to the Arterys radiology platform. Precise measurements are crucial to accurately characterize tumors for cancer treatment plans, as well as to assess the tumor’s growth rate over time or tumor shrinkage in response to therapy. This partnership created a one-click tool to automate the segmentation and measurement of suspicious objects in all imaging modalities, moving one step closer to delivering on a vision of precision medicine and personalized patient care. Amazon Web Services (AWS) — Arterys is working with AWS to launch Amazon HealthLake Imaging, a new HIPAA-eligible capability for storing, sharing, and analyzing medical images at petabyte scale, now available in preview. As an AWS Partner, Arterys is leveraging HealthLake Imaging to enhance performance and responsiveness across its applications, such as Lung AI, which helps physicians analyze and track lung nodules by automatically processing Lung CT scans which delivers improved speed, efficiency, and accuracy of diagnostic decisions. Arterys will demonstrate the use of HealthLake Imaging in the AWS booth (#6958) during RSNA. HealthLake Imaging enables access to medical imaging data with sub-second image retrieval latencies at scale powered by cloud-native APIs and applications from AWS Partners. Providers can realize the cost savings of transitioning to the cloud while preserving low latency performance, eliminating the burden of infrastructure management, and enabling AI/ML to drive increased value from imaging data with support from other services. This allows providers to focus resources on meeting the growing demands of clinical workflows and delivering high-quality patient care. Arterys has been recently acquired by Tempus, a technology company advancing precision medicine through the practical application of AI. Launched in 2015, the company’s platform helps enable physicians to make near real-time, data-driven decisions to deliver personalized patient care and, in parallel, facilitates discovery, development, and delivery of optimal therapeutics to enable doctors to make data-driven treatment decisions, drug companies to make better drugs, and patients to live longer and healthier lives. Together, the two companies aim to better support physicians by providing the AI-enabled solutions necessary to optimize care.
Tempus Web Traffic
Tempus Frequently Asked Questions (FAQ)
When was Tempus founded?
Tempus was founded in 2015.
Where is Tempus's headquarters?
Tempus's headquarters is located at 600 West Chicago Avenue, Chicago.
What is Tempus's latest funding round?
Tempus's latest funding round is Unattributed - II.
How much did Tempus raise?
Tempus raised a total of $1.345B.
Who are the investors of Tempus?
Investors of Tempus include Ares Management, T. Rowe Price, Baillie Gifford & Co., Novo Holdings, Franklin Templeton and 8 more.
Who are Tempus's competitors?
Competitors of Tempus include Validic, nference, Atropos Health, Syapse, Lunit, Sapient, Owkin, NuProbe, Perthera, Mendel.ai and 39 more.
What products does Tempus offer?
Tempus's products include Sequencing and 4 more.
Who are Tempus's customers?
Customers of Tempus include Genmab, Bayer, Kronos and Leap.
Compare Tempus to Competitors
Owkin specializes in AI technologies applied to clinical research with the aim of developing better drugs and treatments for patients. The company's purpose is to empower researchers in hospitals, universities and the biopharma industry to i) understand why drug efficacy varies from patient to patient, ii) improve the drug development process and iii) to help identify key drugs and treatments for each individual patient to improve patient outcomes. The company's precision medicine platform aims to enable medical insights for drug discovery and development by connecting life sciences firms with academic researchers and hospitals. The Owkin platform aims to enable partners to uncover siloed datasets while maintaining patient privacy and securing proprietary data using Federated Learning and innovative collaborative AI technology. The company was founded in 2016 and is based in New York, New York.
ConcertAI specializes in integrated clinical RWD, AI solutions and outcomes science with a large RWD oncology dataset. ConcertAI develops a medical research tool suite that offers care-based oncology research and data analytics.
Evidation measures health in everyday life and enables anyone to participate in research and health programs. Evidation is a two-sided platform that connects individuals and enterprises. On the consumer side, the company assists individuals to participate in research including testing of digital health programs. On the enterprise side, Evidation provides biopharma, med-tech, big tech, academic institutions, professional societies, and government partners the ability to: generate evidence; and design, test, and deploy programs that motivate evidence-based action.
Aetion delivers real-world evidence for life sciences companies, payers, at-risk providers, and regulatory agencies. The Aetion Evidence Platform analyzes data from the real world to produce rapid and scientifically validated answers on treatments, costs, and outcomes. Aetion informs health care's most critical decisions - what works best, for whom, and when - to guide treatment development, commercialization, and payment values into health care's modern era.
Syapse develops applications that enable the use of omics profiles in diagnosing and treating patients at diagnostic companies, research institutions, medical centers, and payers. The Syapse Discovery application provides an end-to-end solution for companies and laboratories deploying sequencing-based diagnostics, from patient sample received to physician report delivered. Discovery's configurable semantic data structure enables users to bring omics data together with traditional medical information to develop and deliver diagnostic tests. The platform's open interfaces enable bioinformaticians and biologists to use their favorite computational tools and annotations. The company was formerly known as BDLicense. Syapse was founded in 2008 and is based in San Francisco, California.
Verana Health assembles clinical databases in medicine to empower physicians and accelerate research for patients. The databases produce drug lifecycle and medical practice insights.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.